nach oben

Erschienen in:

01.04.2014 | Original Article

High GOLPH3 expression is associated with a more aggressive behavior of epithelial ovarian carcinoma

Erschienen in: Virchows Archiv | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

Overexpression of GOLPH3 (Golgi phosphoprotein 3, 34 kDa) is associated with the progression of many solid tumor types leading to an unfavorable clinical outcome. The present study examined the association between GOLPH3 expression and tumor development, clinicopathological factors, and prognosis of epithelial ovarian carcinoma. GOLPH3 expression was examined by immunohistochemistry in 18 normal ovarian samples, 28 benign tumors, 55 serous borderline ovarian tumors, and 135 epithelial ovarian carcinomas. The association of GOLPH3 expression with clinical characteristics, response to chemotherapy, and overall survival of epithelial ovarian carcinoma patients was analyzed on fresh tissue samples. GOLPH3 mRNA and protein expression in ovarian cancer and normal ovarian tissues were detected by real-time quantitative RT-PCR and Western blotting, respectively. The results are the following: (1) GOLPH3 immunostaining localized to the cytoplasm in two patterns, condensed into large granules with perinuclear distribution, and dispersed in the cytoplasm as fine granules. (2) GOLPH3 expression was higher in epithelial ovarian carcinoma than in normal ovarian tissues at the mRNA and protein level. The frequency of high-level expression of GOLPH3 increased progressively from benign (cystadenoma) to borderline neoplasms to malignant lesions. (3) Dispersed cytoplasmic GOLPH3 expression in epithelial ovarian carcinoma patients was highly correlated with FIGO stage (p < 0.001), tumor histological grade (p = 0.003), lymph node involvement (p = 0.001), and chemotherapy response (p = 0.034). (4) A dispersed pattern of GOLPH3 expression was an independent prognostic factor for poor overall survival. Patients with low dispersed cytoplasmic GOLPH3 expression had significantly longer overall survival than patients with high dispersed cytoplasmic expression. In contrast, GOLPH3 condensed expression was not correlated with clinicopathological features, chemotherapy response, or prognosis. GOLPH3 gene expression might play a role in tumorigenesis in epithelial ovarian carcinoma as upregulation of GOLPH3 expression is associated with a more aggressive tumor phenotype. GOLPH3 immunohistochemistry may be of value to predict the outcome of ovarian carcinoma patients.

Runnebaum IB, Stickeler E (2001) Epidemiological and molecular aspects of ovarian cancer risk. J Cancer Res Clin Oncol 127(2):73–79PubMedCrossRef

Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ (2007) Cancer statistics, 2007. CA: Cancer J Clin 57(1):43–66

Visintin I, Feng Z, Longton G, Ward DC, Alvero AB, Lai Y, Tenthorey J, Leiser A, Flores-Saaib R, Yu H, Azori M, Rutherford T, Schwartz PE, Mor G (2008) Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res : Off J Am Assoc Cancer Res 14(4):1065–1072. doi:10.1158/1078-0432.CCR-07-1569 CrossRef

Rustin GJ, Nelstrop AE, McClean P, Brady MF, McGuire WP, Hoskins WJ, Mitchell H, Lambert HE (1996) Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol : Off J Am Soc Clin Oncol 14(5):1545–1551

Ozols RF (2002) Update on the management of ovarian cancer. Cancer J 8(Suppl 1):S22–S30PubMed

Bell AW, Ward MA, Blackstock WP, Freeman HN, Choudhary JS, Lewis AP, Chotai D, Fazel A, Gushue JN, Paiement J, Palcy S, Chevet E, Lafreniere-Roula M, Solari R, Thomas DY, Rowley A, Bergeron JJ (2001) Proteomics characterization of abundant Golgi membrane proteins. J Biol Chem 276(7):5152–5165. doi:10.1074/jbc.M006143200 PubMedCrossRef

Nakashima-Kamimura N, Asoh S, Ishibashi Y, Mukai Y, Shidara Y, Oda H, Munakata K, Goto Y, Ohta S (2005) MIDAS/GPP34, a nuclear gene product, regulates total mitochondrial mass in response to mitochondrial dysfunction. J Cell Sci 118(Pt 22):5357–5367. doi:10.1242/jcs.02645 PubMedCrossRef

Wu CC, Taylor RS, Lane DR, Ladinsky MS, Weisz JA, Howell KE (2000) GMx33: a novel family of trans-Golgi proteins identified by proteomics. Traffic 1(12):963–975PubMed

Snyder CM, Mardones GA, Ladinsky MS, Howell KE (2006) GMx33 associates with the trans-Golgi matrix in a dynamic manner and sorts within tubules exiting the Golgi. Mol Biol Cell 17(1):511–524. doi:10.1091/mbc.E05-07-0682 PubMedCentralPubMedCrossRef

10.

Scott KL, Kabbarah O, Liang MC, Ivanova E, Anagnostou V, Wu J, Dhakal S, Wu M, Chen S, Feinberg T, Huang J, Saci A, Widlund HR, Fisher DE, Xiao Y, Rimm DL, Protopopov A, Wong KK, Chin L (2009) GOLPH3 modulates mTOR signalling and rapamycin sensitivity in cancer. Nature 459(7250):1085–1090. doi:10.1038/nature08109 PubMedCentralPubMedCrossRef

11.

Scott KL, Chin L (2010) Signaling from the Golgi: mechanisms and models for Golgi phosphoprotein 3-mediated oncogenesis. Clin Cancer Res : An Off J Am Assoc Cancer Res 16(8):2229–2234. doi:10.1158/1078-0432.CCR-09-1695 CrossRef

12.

Tavassoli FA, Devilee P (2003) Pathology and genetics of tumours of the breast and female genital organs, vol 4. World Health Organization

13.

Oncology FCoG (2009) Current FIGO staging for cancer of the vagina, fallopian tube, ovary, and gestational trophoblastic neoplasia. Int J Gynaecol Obstet: Off Organ Int Fed Gynaecol Obstet 105(1):3–4CrossRef

14.

Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205–216PubMedCrossRef

15.

Wullschleger S, Loewith R, Hall MN (2006) TOR signaling in growth and metabolism. Cell 124(3):471–484. doi:10.1016/j.cell.2006.01.016 PubMedCrossRef

16.

Clevers H, Nusse R (2012) Wnt/beta-catenin signaling and disease. Cell 149(6):1192–1205. doi:10.1016/j.cell.2012.05.012 PubMedCrossRef

17.

Sabatini DM (2006) mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 6(9):729–734. doi:10.1038/nrc1974 PubMedCrossRef

18.

Ohtsubo K, Marth JD (2006) Glycosylation in cellular mechanisms of health and disease. Cell 126(5):855–867PubMedCrossRef

19.

Li XY, Liu W, Chen SF, Zhang LQ, Li XG, Wang LX (2011) Expression of the Golgi phosphoprotein-3 gene in human gliomas: a pilot study. J Neuro-Oncol 105(2):159–163. doi:10.1007/s11060-011-0573-x CrossRef

20.

Kunigou O, Nagao H, Kawabata N, Ishidou Y, Nagano S, Maeda S, Komiya S, Setoguchi T (2011) Role of GOLPH3 and GOLPH3L in the proliferation of human rhabdomyosarcoma. Oncol Reports 26(5):1337–1342. doi:10.3892/or.2011.1413

21.

Wang JH, Chen XT, Wen ZS, Zheng M, Deng JM, Wang MZ, Lin HX, Chen K, Li J, Yun JP, Luo RZ, Song LB (2012) High expression of GOLPH3 in esophageal squamous cell carcinoma correlates with poor prognosis. PloS One 7(10):e45622. doi:10.1371/journal.pone.0045622 PubMedCentralPubMedCrossRef

22.

Li H, Guo L, Chen SW, Zhao XH, Zhuang SM, Wang LP, Song LB, Song M (2012) GOLPH3 overexpression correlates with tumor progression and poor prognosis in patients with clinically N0 oral tongue cancer. J Transl Med 10:168. doi:10.1186/1479-5876-10-168 PubMedCentralPubMedCrossRef

23.

Zeng Z, Lin H, Zhao X, Liu G, Wang X, Xu R, Chen K, Li J, Song L (2012) Overexpression of GOLPH3 promotes proliferation and tumorigenicity in breast cancer via suppression of the FOXO1 transcription factor. Clin Cancer Res: An Off J Am Assoc Cancer Res 18(15):4059–4069. doi:10.1158/1078-0432.CCR-11-3156 CrossRef

24.

Hua X, Yu L, Pan W, Huang X, Liao Z, Xian Q, Fang L, Shen H (2012) Increased expression of Golgi phosphoprotein-3 is associated with tumor aggressiveness and poor prognosis of prostate cancer. Diagn Pathol 7:127. doi:10.1186/1746-1596-7-127 PubMedCentralPubMedCrossRef

25.

Ali MF, Chachadi VB, Petrosyan A, Cheng PW (2012) Golgi phosphoprotein 3 determines cell binding properties under dynamic flow by controlling Golgi localization of core 2 N-acetylglucosaminyltransferase 1. J Biol Chem 287(47):39564–39577. doi:10.1074/jbc.M112.346528 PubMedCentralPubMedCrossRef

26.

St Hill CA, Baharo-Hassan D, Farooqui M (2011) C2-O-sLeX glycoproteins are E-selectin ligands that regulate invasion of human colon and hepatic carcinoma cells. PloS One 6(1):e16281. doi:10.1371/journal.pone.0016281 PubMedCentralPubMedCrossRef

27.

Carlow DA, Gossens K, Naus S, Veerman KM, Seo W, Ziltener HJ (2009) PSGL-1 function in immunity and steady state homeostasis. Immunol Rev 230(1):75–96. doi:10.1111/j.1600-065X.2009.00797.x PubMedCrossRef

28.

Beum PV, Singh J, Burdick M, Hollingsworth MA, Cheng PW (1999) Expression of core 2 beta-1,6-N-acetylglucosaminyltransferase in a human pancreatic cancer cell line results in altered expression of MUC1 tumor-associated epitopes. J Biol Chem 274(35):24641–24648PubMedCrossRef

29.

Kupryjanczyk J, Szymanska T, Madry R, Timorek A, Stelmachow J, Karpinska G, Rembiszewska A, Ziolkowska I, Kraszewska E, Debniak J, Emerich J, Ulanska M, Pluzanska A, Jedryka M, Goluda M, Chudecka-Glaz A, Rzepka-Gorska I, Klimek M, Urbanski K, Breborowicz J, Zielinski J, Markowska J (2003) Evaluation of clinical significance of TP53, BCL-2, BAX and MEK1 expression in 229 ovarian carcinomas treated with platinum-based regimen. Br J Cancer 88(6):848–854. doi:10.1038/sj.bjc.6600789 PubMedCentralPubMedCrossRef

30.

de Graeff P, Crijns AP, Ten Hoor KA, Klip HG, Hollema H, Oien K, Bartlett JM, Wisman GB, de Bock GH, de Vries EG, de Jong S, van der Zee AG (2008) The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer. Br J Cancer 99(2):341–349. doi:10.1038/sj.bjc.6604471 PubMedCentralPubMedCrossRef

31.

Zhou J, Xu T, Qin R, Yan Y, Chen C, Chen Y, Yu H, Xia C, Lu Y, Ding X, Wang Y, Cai X, Chen J (2012) Overexpression of Golgi phosphoprotein-3 (GOLPH3) in glioblastoma multiforme is associated with worse prognosis. J Neuro-Oncol 110(2):195–203. doi:10.1007/s11060-012-0970-9 CrossRef

Titel: High GOLPH3 expression is associated with a more aggressive behavior of epithelial ovarian carcinoma
Publikationsdatum: 01.04.2014
Erschienen in: Virchows Archiv / Ausgabe 4/2014
Print ISSN: 0945-6317
Elektronische ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-014-1536-3

Springer Medizin

High GOLPH3 expression is associated with a more aggressive behavior of epithelial ovarian carcinoma

Abstract

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren

Personalisierte Medizin in der Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2014

In pulmonary lymphangioleiomyomatosis expression of progesterone receptor is frequently higher than that of estrogen receptor

Multilayered epithelium at the gastroesophageal junction is a marker of gastroesophageal reflux disease: data from a prospective Central European multicenter study (histoGERD trial)

Morphology predicts BRAF V600E mutation in papillary thyroid carcinoma: an interobserver reproducibility study

microRNA expression might predict prognosis of epithelial hepatoblastoma

Retroperitoneal dedifferentiated liposarcoma lacking MDM2 amplification in a patient with a germ line CHEK2 mutation

Lack of supportive evidence for the use of immunohistochemical staining to identify occult regional lymph node metastases in primary lung cancer

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren

Personalisierte Medizin in der Onkologie